Conditions: Biliary Tract Cancer Gallbladder Cancer
Keywords: Unresectable metastatic biliary tract gallbladder cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 31
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine disease response of GEMOX-Panitumumab (GEMOX-P) in KRAS/ BRAF wild-type, Stage IV, biliary tract and gallbladder cancer patients who have previously not received chemotherapy. This study will also examine the potential toxicities, progression-free and overall survival in this population.

Detailed description:

Arms:
arm 1: Panitumumab 6mg/kg on days 1 and 15 of every cycle (28 days); Gemcitabine 1000mg/m2 on days 1 and 15 of every cycle (28 days); Oxaliplatin 85mg/m2 on days 1 and 15 of every cycle (28 days)

Interventions: intervention 1: Panitumumab intervention 2: oxaliplatin intervention 3: gemcitabine
Intervention descriptions: intervention 1: Day 1 and 15 = 6 mg/kg IV intervention 2: Days 1 and 15 = 85mg/m2 IV intervention 3: Days 1 and 15 = 1000 mg/m2 IV

Protocol document: